(Q37987211)

26 August 2017

title

Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

26 August 2017

main subject

1 reference

1 reference

ChEBI release 2020-05-28

1

Kate McKeage

1 reference

26 August 2017

publication date

1 March 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

72

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

543-563

1 reference

Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Indacaterol: in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Bronchodilator effects of indacaterol and formoterol in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Indacaterol once-daily is equally effective dosed in the evening or morning in COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Clinical relevance of constant power exercise duration changes in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Safety of indacaterol in the treatment of patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

The risks and benefits of indacaterol--the FDA's review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Electrophysiologic effects of salbutamol, a beta2-selective agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Chronic obstructive pulmonary disease and the risk of cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208490-000000000-00000

Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium

21 January 2018

1 reference

12 December 2020

Effect of indacaterol on exercise endurance and lung hyperinflation in COPD

1 reference

12 December 2020

Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data

1 reference

12 December 2020

Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study

1 reference

12 December 2020

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone

1 reference

12 December 2020

Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study

1 reference

12 December 2020

A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire

1 reference

12 December 2020

Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison

1 reference

12 December 2020

Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD

1 reference

12 December 2020

Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study.

1 reference

12 December 2020

Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD.

1 reference

12 December 2020

24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol

1 reference

12 December 2020

10.2165/11208490-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1048814607

0 references

1 reference